로딩 중…
StockDiggingStockDigging

CareDx, Inc

CDNA· NASDAQ
$53.83-0.83%
2026-09-18

Financials

Valuation Metrics

CareDx, Inc's Market Cap is $2.78B. At end of 2025 it was $963M. Ranked #1792 of 3,121 in US market (top 57%), #647 of 1,463 on NASDAQ (top 44%), #107 of 205 in Health Care Equipment & Services (top 52%) by Market Cap.

Investment Metrics(as of 2026-09-18)

MetricValue
Size
Market Cap$2.78B
Revenue$458M
Net Income$111M
Total Assets$533M
Net Assets$426M
Employees763
Value
P/E25.05x
P/B6.53x
PEG0.22x
P/S6.07x
EV/EBITDA155.96x
FCF Yield3.06%
Profitability
ROE26.08%
ROA20.83%
Op. Margin-0.92%
Revenue Growth34.41%
Earnings Growth114.80%
Financial Health
Debt Ratio25.23%
Total Debt$19M
FCF$85M
Cash$374M
Current Ratio4.58x
Net Debt/EBITDA-22.78x
Performance
1Y Return264.45%
1M Return15.74%
From 52W High-2.41%
1Y MDD-23.64%
Trading
Volume1,181,614 shares
Trading Value$64M
Per Share
EPS$2.15
BPS$8.24

Company Info

CEO John Walter Hanna Jr.
Employees 763
HQ Brisbane, US

CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.